卡马西平,临床注释-2,变异和临床注释数据

卡马西平

临床注释ID

981419263

药物名称(英)

carbamazepine

变异单倍型

HLA-B*15:02:01, HLA-B*15:11:01

基因

HLA-B

证据级别

1A

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Toxicity

表现型类别

毒性

分数

413.5

PMID计数

49

计数的证据

59

表现型

嗜酸性粒细胞增多和全身症状的药物反应；表皮坏死松解症，毒性；斑丘疹；严重皮肤不良反应；Stevens-Johnson 综合征

表现型(英)

drug reaction with eosinophilia and systemic symptoms;Epidermal Necrolysis, Toxic;Maculopapular Exanthema;severe cutaneous adverse reactions;Stevens-Johnson Syndrome

最新日期

2022/3/3 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/981419263

专业人口(英)

Pediatric

专业人口

儿科

临床等位基因

id	等位基因	注释文本
831	*15:11:01	Patients with one or two copies of the HLA-B15:11:01 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with carbamazepine as compared to patients with no HLA-B15:11:01 alleles or negative for the HLA-B*15:11:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of carbamazepine-induced adverse reactions.
830	*15:02:01	Patients with one or two copies of the HLA-B15:02:01 allele may have an increased risk of Severe Cutaneous Adverse Reactions when treated with carbamazepine as compared to patients with no HLA-B15:02:01 alleles or negative for the HLA-B*15:02:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of carbamazepine-induced adverse reactions.

临床证据

id	证据的ID	总结
527	1451780623	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine or lamotrigine.
526	1451641227	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
525	1451641160	HLA-B *15:11:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.
524	1451504120	HLA-B *15:11:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine.
523	1451431060	HLA-B *15:02:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.
522	981349408	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine.
521	1451305960	HLA-B *15:02:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine.
520	1184755407	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.
519	1449147028	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine.
518	1449004794	HLA-B *15:02:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.
517	1448635647	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine.
516	1448525687	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.
515	1448261069	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.
514	1447983639	HLA-B *15:02:01 is associated with risk of Stevens-Johnson Syndrome when treated with carbamazepine in women with Epilepsy.
513	1447980932	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic, Exanthema and Stevens-Johnson Syndrome when treated with carbamazepine in people with Bipolar Disorder or Epilepsy.
512	1447959759	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine in children with schizencephaly.
511	1446902307	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.
510	1446895471	HLA-B *15:02:01 is associated with Epidermal Necrolysis, Toxic when treated with carbamazepine.
509	1444707960	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
508	1444707937	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.
507	1185003427	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.
506	1185003386	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.
505	1184988662	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.
504	1184987994	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine, phenobarbital or phenytoin in children.
503	1184469237	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.
502	1184469192	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
501	1184469104	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.
500	1184469086	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
499	1184469071	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine, oxcarbazepine and phenobarbital in children with Epilepsy.
498	1184468423	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
497	1184468379	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in children.
496	1184468322	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
495	1184468301	HLA-B *15:11:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
494	1184468294	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
493	1184468042	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.
492	1184467942	HLA-B *15:11:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.
491	1184467933	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.
490	1184466933	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with neuropathic pain.
489	1184466899	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
488	1184466880	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
487	1184466803	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
486	1184466792	HLA-B *15:11:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
485	1184421854	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
484	1184412194	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
483	1184407607	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.
482	1183702093	HLA-B *15:11:01 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.
481	1183702087	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.
480	1183702071	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.
479	1183680856	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.
478	994166507	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.
477	981859117	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine or phenytoin in people with Epilepsy.
476	981859096	HLA-B *15:02:01 is associated with increased risk of cutaneous reactions when treated with antiepileptics or carbamazepine in Epilepsy.
475	981482101	HLA-B *15:02:01 is associated with increased risk of carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with carbamazepine.
474	981349415	HLA-B *15:02:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine.
473	981349402	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.
472	981349387	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.
471	PA166104780	Annotation of FDA Label for carbamazepine and HLA-B
470	PA166265162	Annotation of DPWG Guideline for carbamazepine and HLA-B
469	PA166105008	Annotation of CPIC Guideline for carbamazepine and HLA-A, HLA-B

临床病史

id	类型	评论
1246	Update	Added *1511 allele and attached literature. Attached DPWG guidelines.
1245	Note	1184996938 (the separate annotation on *1511) is now retired
1244	Update	Added PMID 34350628 to evidence.
1243	Update	Added PMID:33910375
1242	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1241	Update	Added FDA label
1240	Update	Removed tag for DRESS since this is not in the CPIC guideline for this allele which is for SJS/TEN. Added conflict statement.
1239	Update	Tagged DRESS and SCAR
1238	Update	Level 1A because of guidelines. Added SCAR into text.
1237	Update	Updated OMB race to appropriate biogeographical group
1236	Update
1235	Create	Created

最新招商产品更多>>